These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 35916995)

  • 41. [Continue to use the bivalent HPV vaccine; bivalent vaccine more effective than expected].
    Postma MJ; Wilschut JC
    Ned Tijdschr Geneeskd; 2020 Jan; 164():. PubMed ID: 32073795
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model.
    Jit M; Brisson M; Laprise JF; Choi YH
    BMJ; 2015 Jan; 350():g7584. PubMed ID: 25567037
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy: a combined follow-up analysis of data from two randomised, double-blind, multicentre, phase 3 trials.
    Mariz FC; Gray P; Bender N; Eriksson T; Kann H; Apter D; Paavonen J; Pajunen E; Prager KM; Sehr P; Surcel HM; Waterboer T; Müller M; Pawlita M; Lehtinen M
    Lancet Infect Dis; 2021 Oct; 21(10):1458-1468. PubMed ID: 34081923
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Potential cost-effectiveness of the nonavalent human papillomavirus (HPV) vaccine.
    Drolet M; Laprise JF; Boily MC; Franco EL; Brisson M
    Int J Cancer; 2014 May; 134(9):2264-8. PubMed ID: 24174175
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The quadrivalent human papillomavirus vaccine: potential factors in effectiveness.
    Zonfrillo NJ; Hackley B
    J Midwifery Womens Health; 2008; 53(3):188-194. PubMed ID: 18455092
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Knowledge, acceptance, and willingness to pay for human papilloma virus (HPV) vaccination among female parents in Thailand.
    Kruiroongroj S; Chaikledkaew U; Thavorncharoensap M
    Asian Pac J Cancer Prev; 2014; 15(13):5469-74. PubMed ID: 25041020
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: The value of stratifying guidelines.
    Pedersen K; Burger EA; Nygård M; Kristiansen IS; Kim JJ
    Eur J Cancer; 2018 Mar; 91():68-75. PubMed ID: 29335156
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cost-effectiveness and epidemiological impact of gender-neutral HPV vaccination in Spain.
    Linertová R; Guirado-Fuentes C; Mar-Medina J; Teljeur C
    Hum Vaccin Immunother; 2022 Nov; 18(6):2127983. PubMed ID: 36347243
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The cost-effectiveness of human papillomavirus vaccination in the Philippines.
    Llave CL; Uy MEV; Lam HY; Aldaba JG; Yacapin CC; Miranda MB; Valverde HA; Silva WT; Nawaz S; Slavkovsky RC; Mooney J; Vodicka EL
    Vaccine; 2022 Jun; 40(27):3802-3811. PubMed ID: 35606237
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study.
    Jit M; Brisson M; Portnoy A; Hutubessy R
    Lancet Glob Health; 2014 Jul; 2(7):e406-14. PubMed ID: 25103394
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Estimating the epidemiological impact and cost-effectiveness profile of a nonavalent HPV vaccine in Spain.
    De La Fuente J; Hernandez Aguado JJ; San Martín M; Ramirez Boix P; Cedillo Gómez S; López N
    Hum Vaccin Immunother; 2019; 15(7-8):1949-1961. PubMed ID: 30698488
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Costs of delivering human papillomavirus vaccination to schoolgirls in Mwanza Region, Tanzania.
    Quentin W; Terris-Prestholt F; Changalucha J; Soteli S; Edmunds WJ; Hutubessy R; Ross DA; Kapiga S; Hayes R; Watson-Jones D
    BMC Med; 2012 Nov; 10():137. PubMed ID: 23148516
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis.
    Malagón T; Drolet M; Boily MC; Franco EL; Jit M; Brisson J; Brisson M
    Lancet Infect Dis; 2012 Oct; 12(10):781-9. PubMed ID: 22920953
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Optimal Cervical Cancer Screening in Women Vaccinated Against Human Papillomavirus.
    Kim JJ; Burger EA; Sy S; Campos NG
    J Natl Cancer Inst; 2017 Feb; 109(2):. PubMed ID: 27754955
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Health and economic benefits of single-dose HPV vaccination in a Gavi-eligible country.
    Burger EA; Campos NG; Sy S; Regan C; Kim JJ
    Vaccine; 2018 Aug; 36(32 Pt A):4823-4829. PubMed ID: 29807710
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Identifying a Single Optimal Integrated Cervical Cancer Prevention Policy in Norway: A Cost-Effectiveness Analysis.
    Portnoy A; Pedersen K; Nygård M; Trogstad L; Kim JJ; Burger EA
    Med Decis Making; 2022 Aug; 42(6):795-807. PubMed ID: 35255741
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Evaluation of the cost-effectiveness of two alternative human papillomavirus vaccines as prophylaxis against uterine cervical cancer].
    Bolaños-Díaz R; Tejada RA; Beltrán J; Escobedo-Palza S
    Rev Peru Med Exp Salud Publica; 2016; 33(3):411-418. PubMed ID: 27831602
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Domestic HPV vaccine price and economic returns for cervical cancer prevention in China: a cost-effectiveness analysis.
    Zou Z; Fairley CK; Ong JJ; Hocking J; Canfell K; Ma X; Chow EPF; Xu X; Zhang L; Zhuang G
    Lancet Glob Health; 2020 Oct; 8(10):e1335-e1344. PubMed ID: 32971056
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Human papillomavirus (HPV) vaccination for the prevention of HPV 16/18 induced cervical cancer and its precursors.
    Damm O; Nocon M; Roll S; Vauth C; Willich S; Greiner W
    GMS Health Technol Assess; 2009 Mar; 5():Doc04. PubMed ID: 21289891
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis.
    Van de Velde N; Boily MC; Drolet M; Franco EL; Mayrand MH; Kliewer EV; Coutlée F; Laprise JF; Malagón T; Brisson M
    J Natl Cancer Inst; 2012 Nov; 104(22):1712-23. PubMed ID: 23104323
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.